Apimeds Pharmaceuticals US, Inc
APUS
Rank in Stocks
#31024
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Share Price
$2.36
Last synced: 2026-11-11
Market Cap
$3.85M
Change (1 day)
-12.27%
Change (1 year)
-91.19%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Apimeds Pharmaceuticals US, Inc (APUS)
Category
Healthcare
EPS for Apimeds Pharmaceuticals US, Inc (APUS)
EPS as of June 2026 TTM: $-49.29
According to Apimeds Pharmaceuticals US, Inc's latest financial reports, its current EPS (TTM) is $-49.29. At the end of 2025 the company had an EPS of $-5.50, an increase over its 2024 EPS of $-12.00.
EPS history for Apimeds Pharmaceuticals US, Inc from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-49.29 | 796.18% |
| 2025 | $-5.50 | -54.17% |
| 2024 | $-12.00 | 77.78% |
| 2023 | $-6.75 | 16.38% |
| 2022 | $-5.80 | -34.83% |
| 2021 | $-8.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -131.77% |
US
|
|
| $-7.07 | -85.66% |
US
|
|
| $-5.29 | -89.27% |
AU
|
|
| $12.88 | -126.13% |
BE
|
|
| $21.56 | -143.74% |
NL
|
Questions about Apimeds Pharmaceuticals US, Inc's earnings per share (EPS)
What is Apimeds Pharmaceuticals US, Inc's earnings per share (EPS)?
Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) over the last twelve months is $-49.29, as of Jun 2026.
What was Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) in 2025?
In 2025, Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) was $-5.50, compared with $-12.00 in 2024.
How has Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) changed since 2021?
From 2021 to 2025, Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) was highest in 2025 ($-5.50) and lowest in 2024 ($-12.00).
How does Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) compare with similar companies?
Apimeds Pharmaceuticals US, Inc's earnings per share (EPS) ($-49.29) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.